{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:24:08Z","timestamp":1791357848676,"version":"4.3.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2025JJ80494"],"award-info":[{"award-number":["2025JJ80494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10637-026-01596-1","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:51:13Z","timestamp":1767937873000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical features, treatment and outcomes of pembrolizumab induced autoimmune hemolytic anemia"],"prefix":"10.1007","volume":"44","author":[{"given":"Jieqiong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"11","key":"1596_CR1","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW et al (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777\u20132789. https:\/\/doi.org\/10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"issue":"26","key":"1596_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372(26):2521\u20132532. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"issue":"7","key":"1596_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","volume":"36","author":"E Felip","year":"2025","unstructured":"Felip E, Rojas CI, Schenker M et al (2025) Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475a\u2013d77 trial. Ann Oncol 36(7):775\u2013785. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.012","journal-title":"Ann Oncol"},{"issue":"4","key":"1596_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R et al (2023) Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol 41(4):790\u2013802. https:\/\/doi.org\/10.1200\/JCO.21.02508","journal-title":"J Clin Oncol"},{"issue":"12","key":"1596_CR5","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1159\/000543520","volume":"103","author":"W Yin","year":"2025","unstructured":"Yin W, Tan F, Zhou L et al (2025) Analysis of immune-related adverse events of Pembrolizumab using FAERS database. Oncology 103(12):1147\u20131159. https:\/\/doi.org\/10.1159\/000543520","journal-title":"Oncology"},{"issue":"5","key":"1596_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis EJ, Salem JE, Young A et al (2019) Hematologic complications of immune checkpoint inhibitors. Oncologist 24(5):584\u2013588. https:\/\/doi.org\/10.1634\/theoncologist.2018-0574","journal-title":"Oncologist"},{"issue":"1","key":"1596_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-020-00208-7","volume":"17","author":"SS Michalak","year":"2020","unstructured":"Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J et al (2020) Autoimmune hemolytic anemia: current knowledge and perspectives. Immun Ageing 17(1):38. https:\/\/doi.org\/10.1186\/s12979-020-00208-7","journal-title":"Immun Ageing"},{"issue":"5","key":"1596_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ajh.25448","volume":"94","author":"RK Leaf","year":"2019","unstructured":"Leaf RK, Ferreri C, Rangachari D et al (2019) Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol 94(5):563\u2013574. https:\/\/doi.org\/10.1002\/ajh.25448","journal-title":"Am J Hematol"},{"issue":"1","key":"1596_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00566-2","volume":"10","author":"M Michel","year":"2024","unstructured":"Michel M, Crickx E, Fattizzo B et al (2024) Autoimmune haemolytic anaemias. Nat Rev Dis Primers 10(1):82. https:\/\/doi.org\/10.1038\/s41572-024-00566-2","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"1596_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ajh.10062","volume":"69","author":"BC Gehrs","year":"2002","unstructured":"Gehrs BC, Friedberg RC (2002) Autoimmune hemolytic anemia. Am J Hematol 69(4):258\u2013271. https:\/\/doi.org\/10.1002\/ajh.10062","journal-title":"Am J Hematol"},{"issue":"1","key":"1596_CR11","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T et al (2019) Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6(1):e48\u2013e57. https:\/\/doi.org\/10.1016\/S2352-3026(18)30175-3","journal-title":"Lancet Haematol"},{"key":"1596_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014.E","volume":"122","author":"JM Michot","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A et al (2019) Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 122:72\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.014.E","journal-title":"Eur J Cancer"},{"issue":"2","key":"1596_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ejh.13187","volume":"102","author":"GE Tanios","year":"2019","unstructured":"Tanios GE, Doley PB, Munker R (2019) Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol 102(2):157\u2013162. https:\/\/doi.org\/10.1111\/ejh.13187","journal-title":"Eur J Haematol"},{"key":"1596_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/CJI.000000000000345","volume":"44","author":"JW Smithy","year":"2021","unstructured":"Smithy JW, Pianko MJ, Maher C et al (2021) Checkpoint blockade in melanoma patients with underlying chronic lymphocytic leukemia. J Immunother 44:9\u201315. https:\/\/doi.org\/10.1097\/CJI.000000000000345","journal-title":"J Immunother"},{"issue":"3","key":"1596_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.14478","volume":"176","author":"QA Hill","year":"2017","unstructured":"Hill QA, Stamps R, Massey E et al (2017) The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol 176(3):395\u2013411. https:\/\/doi.org\/10.1111\/bjh.14478","journal-title":"Br J Haematol"},{"issue":"4","key":"1596_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bcmd.2013.12.003","volume":"52","author":"GB Segel","year":"2014","unstructured":"Segel GB, Lichtman MA (2014) Direct antiglobulin (\u201cCoombs\u201d) test-negative autoimmune hemolytic anemia: a review. Blood Cells Mol Dis 52(4):152\u2013160. https:\/\/doi.org\/10.1016\/j.bcmd.2013.12.003","journal-title":"Blood Cells Mol Dis"},{"key":"1596_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00009","volume":"5","author":"DZ de Back","year":"2014","unstructured":"de Back DZ, Kostova EB, van Kraaij M et al (2014) Of macrophages and red blood cells; a complex love story. Front Physiol 5:9. https:\/\/doi.org\/10.3389\/fphys.2014.00009","journal-title":"Front Physiol"},{"issue":"6","key":"1596_CR18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.20102538","volume":"208","author":"EE Zoller","year":"2011","unstructured":"Zoller EE, Lykens JE, Terrell CE et al (2011) Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 208(6):1203\u20131214. https:\/\/doi.org\/10.1084\/jem.20102538","journal-title":"J Exp Med"},{"key":"1596_CR19","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.73","author":"G Garratty","year":"2009","unstructured":"Garratty G (2009) Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. https:\/\/doi.org\/10.1182\/asheducation-2009.1.73","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"1596_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H et al (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8(5):765\u2013772. https:\/\/doi.org\/10.1093\/intimm\/8.5.765","journal-title":"Int Immunol"},{"issue":"10","key":"1596_CR21","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","volume":"10","author":"H Nishimura","year":"1998","unstructured":"Nishimura H, Minato N, Nakano T et al (1998) Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 10(10):1563\u20131572. https:\/\/doi.org\/10.1093\/intimm\/10.10.1563","journal-title":"Int Immunol"},{"key":"1596_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-35","volume":"7","author":"E von Euw","year":"2009","unstructured":"von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A (2009) CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 7:35. https:\/\/doi.org\/10.1186\/1479-5876-7-35","journal-title":"J Transl Med"},{"key":"1596_CR23","first-page":"9","volume":"8","author":"J Sun","year":"2008","unstructured":"Sun J, Schiffman J, Raghunath A et al (2008) Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8:9","journal-title":"Cancer Immun"},{"issue":"7","key":"1596_CR24","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ajh.27339","volume":"99","author":"M Pla\u00e7ais","year":"2024","unstructured":"Pla\u00e7ais M, Laparra A, Maria ATJ et al (2024) Drug-induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome. Am J Hematol 99(7):1427\u20131430. https:\/\/doi.org\/10.1002\/ajh.27339","journal-title":"Am J Hematol"},{"issue":"17","key":"1596_CR25","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"12","key":"1596_CR26","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"issue":"12","key":"1596_CR27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1055\/a-1010-3409","volume":"45","author":"C Pfhler","year":"2019","unstructured":"Pfhler C, Koch S, Weber L et al (2019) Autoimmune hemolytic anemia as a rare side effect of a therapy with Pembrolizumab for metastatic melanoma. Aktuelle Dermatol 45(12):593\u2013598. https:\/\/doi.org\/10.1055\/a-1010-3409","journal-title":"Aktuelle Dermatol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01596-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01596-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01596-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:53:39Z","timestamp":1777294419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01596-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01596-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}